Clinical Trial Update: Phase 2 Clinical Trial of KH617 [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of KH617 for recurrent glioblastoma is listed as not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• KH617

Snippet

Sponsor: Sichuan Honghe Biotechnology Co., Ltd. | Conditions: Recurrent Glioblastoma | Phase 2 | Status: NOT_YET_RECRUITING